Pharma: Page 2

  • Image attribution tooltip
    Jacob Bell / BioPharma Dive

    FDA approves oral version of Mitsubishi's ALS drug

    Called Radicava ORS, this version is taken by mouth rather than via an hourlong infusion, which may help improve the drug's convenience and use.

    By May 13, 2022
  • Image attribution tooltip
    Permission granted by Bristol-Myers Squibb

    Key Bristol Myers drug holds up in long-term psoriasis study

    Deucravacitnib, forecast by Bristol Myers to hit $4 billion in peak sales, is under FDA review with an approval decision due by September. The agency's view of its safety will be key to its future.

    By May 12, 2022
  • Trendline

    The expanding world of RNA therapies

    Vaccines from BioNTech and Moderna proved the power of messenger RNA in medicine. A growing field of RNA-targeting therapies is advancing alongside them.

    By BioPharma Dive staff
  • Image attribution tooltip
    Permission granted by Bristol-Myers Squibb

    Bristol Myers acquires BridgeBio drug aimed at emerging cancer target

    The pharma will pay $90 million to license BridgeBio's experimental candidate, joining a lengthening list of large drugmakers aiming to treat cancer by blocking a protein called SHP2.

    By May 12, 2022
  • Image attribution tooltip
    iStock via Getty Images

    Roche cancer immunotherapy fails another trial, casting doubt on emerging drug class

    A treatment combination involving Roche's anti-TIGIT medicine tiragolumab missed its goal in a Phase 3 lung cancer study that was viewed as a proof point for the drug class.

    By May 11, 2022
  • Image attribution tooltip
    Dan Kitwood via Getty Images

    Pfizer to acquire Biohaven in $11.6B bet on biotech's migraine drugs

    The deal, which hands Pfizer full rights to the biotech's fast-selling Nurtec ODT, could provide a much needed spark for the sector after months of stock market declines. 

    By , Updated May 10, 2022
  • Image attribution tooltip
    Mario Tama via Getty Images

    J&J ends hepatitis B, HPV vaccine work with Bavarian Nordic

    The companies' hepatitis B program never reached clinical testing, while J&J said it would no longer develop an HPV vaccine because of the "widespread uptake" of effective shots from other companies.

    By May 9, 2022
  • Image attribution tooltip

    Novartis suspends production of two radiopharmaceutical drugs over quality concerns

    Due to potential issues in manufacturing, the pharma is halting deliveries of two cancer drugs, Lutathera and Pluvicto, in the U.S. and Canada, a setback for a business in which the company has invested heavily.  

    By May 6, 2022
  • Image attribution tooltip

    Sponsored by Acceleration Point

    Digital key opinion leaders: who are they?

    As scientific discussions increase online, Medical Affairs teams need ways to listen to conversations.  

    May 2, 2022
  • Image attribution tooltip
    Permission granted by Bristol-Myers Squibb

    Bristol Myers wins FDA approval for first drug to treat inherited heart condition

    Bristol Myers paid $13 billion to acquire the drug's maker, MyoKardia, and expects it to become a blockbuster. But a tricky dosing regimen, as well as safety concerns, could challenge the pharmaceutical giant's lofty forecast. 

    By April 28, 2022
  • Lilly's closely watched diabetes drug scores in obesity trial

    Called tirzepatide, the drug significantly lowered weight loss in a large study, findings that add to growing evidence that a class of medicines originally meant for diabetes may effectively treat obesity.

    By April 28, 2022
  • Image attribution tooltip
    National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Micrograph]. Retrieved from Flickr.

    FDA sets back Novartis' best chance at a COVID-19 drug

    The agency indicated another trial of the drug, developed by Molecular Partners, will be needed. But whether such a study is doable is yet to be determined, according to Novartis' CEO Vas Narasimhan.

    By Kristin Jensen • April 27, 2022
  • Image attribution tooltip

    Novartis names longtime analyst as top dealmaker amid organizational shakeup

    Novartis said in an earnings presentation Tuesday that it hired biotech analyst Ronny Gal as chief strategy and growth officer and revealed more details about planned layoffs as the company restructures.

    By April 26, 2022
  • Nektar begins sweeping layoffs after $2B Bristol Myers deal falls apart

    Loss of the lucrative partnership has triggered a wide-ranging restructuring that will pare down Nektar’s workforce by about 70%.

    By April 26, 2022
  • Image attribution tooltip
    Courtesy of Roche

    Roche stumbles in latest setback for an emerging group of breast cancer drugs

    The Phase 2 failure marks the second negative result in two months for a closely watched group of medicines, known as SERDs, that are being developed by several large pharmaceutical companies.

    By April 25, 2022
  • Image attribution tooltip

    Sponsored by Medscape

    Connect to the conversation: Pediatric mental health

    More children than ever are experiencing mental health issues, so what can parents and loved ones do to help address these issues and prevent them before they start?

    April 25, 2022
  • Image attribution tooltip
    Elizabeth Regan / Industry Dive

    Drug price hikes moderate as rebates rise, report finds

    List prices for branded medicines rose by nearly 5% last year, according to IQVIA, a figure that fell to 1% after accounting for rebates and discounts.

    By April 21, 2022
  • AbbVie ends research alliance on BioArctic Parkinson's drug

    The company's decision is a blow to Sweden-based BioArctic, which two months ago was expecting AbbVie to advance the drug into Phase 2 this year.

    By April 20, 2022
  • Image attribution tooltip
    Erik S. Lesser via Getty Images

    Merck brings former executive back to lead ex-US pharmaceuticals business

    Joseph Romanelli is returning from a short stint at the Chinese drugmaker Ji Xing Pharmaceuticals. In his new role at Merck, he will oversee more than 75 markets outside the U.S. and about 14,000 employees.

    By Kristin Jensen • April 20, 2022
  • Image attribution tooltip
    Permission granted by Johnson & Johnson

    J&J cuts COVID vaccine sales forecasts, citing high supplies and lagging demand

    The drugmaker previously expected up to $3.5 billion in 2022 revenue, but uncertainty about the pace of vaccinations led it to suspend investor guidance.

    By April 19, 2022
  • Image attribution tooltip
    Courtesy of Gilead

    Gilead gets cell therapy boost with FDA clearance of Maryland factory

    The new site in Maryland will be used to produce Yescarta, which this month won an expanded approval that substantially widens its market.

    By April 19, 2022
  • Bristol Myers scraps $2B Nektar partnership after trial failures

    The companies have halted testing in kidney and bladder cancer, one month after ending a skin cancer study. Nektar executives are now preparing plans to conserve cash.

    By April 18, 2022
  • Image attribution tooltip
    Permission granted by GoodRx
    Sponsored by GoodRx

    Inflation is forcing prioritization of healthcare spending — are you ready?

    Inflation means your customers' money doesn't travel as far as it did a few weeks ago.

    April 18, 2022
  • Image attribution tooltip

    AbbVie, Genmab, with new data, prep FDA application for dual-acting cancer drug

    Fresh trial results intensify competition with Roche to deliver the first lymphoma drug that marries antibody technology with an immunotherapy pathway.

    By April 14, 2022
  • Image attribution tooltip
    Md Saiful Islam Khan via Getty Images

    UK bid to battle antibiotic resistance yields first subscription-style plan

    Pfizer and Shionogi could receive 10 million pounds, or about $13 million, a year for new antibiotics. International participation might be needed to further spur development, however.

    By April 12, 2022
  • Image attribution tooltip
    Maddie Meyer via Getty Images

    Pfizer, Moderna name new finance chiefs amid surging revenue

    Pfizer is bringing in former Lowe's and CVS Health executive David Denton, while Moderna hired Jorge Gomez, previously CFO at Cardinal Health. Both take the reins as their new companies face strategic questions.

    By April 11, 2022